The effects of buspirone (0.5 mg/kg) on the neuroendocrine and serotonergic responses to stress were monitored in rats. Exposure to 2-h of restraint stress increased circulating levels of corticosterone, noradrenaline and glucose. The metabolism of 5-hydroxytryptamine (5-HT; serotonin) increased in the brain. Prior administration of buspirone did not alter levels of corticosterone, noradrenalin...

5-Hydroxytryptamine 1A (5-HT1A) receptor agonists reverse the hypotensive and sympathoinhibitory responses to severe hemorrhage in rats. To determine whether 5-HT1A receptor-mediated pressor responses in hypovolemic animals are due to sympathoexcitation and/or direct vasoconstriction, blood pressure (BP), heart rate (HR), and renal sympathetic nerve activity (RSNA) responses to the partial 5-HT...

BACKGROUND The purpose of this study was to test the hypothesis that the addition of buspirone, a partial agonist of 5HT1A receptor, to ongoing treatment with typical antipsychotics would improve the positive and negative symptoms in patients with chronic schizophrenia. MATERIALS AND METHODS In this study, 50 patients including 40 male and 10 female were recruited with chronic schizophrenia w...

We evaluated cortisol response to buspirone in extended abstinent alcoholic patients to determine 5-HT1A receptor sensitivity in alcoholism. Alcoholic patients were inpatients with an extended abstinent period of at least 3 months. Alcoholics had a significantly lower cortisol level than did the normal controls from 60 min through to 150 min after administration of 30 mg buspirone. Our results ...

Buspirone is a potent anxiolytic that decreases serotonin transmission. Changes in electrolyte balance, plasma osmolality and systolic blood pressure are often associated with stress-induced anxiety in rats as well as in human but effects of buspirone on changes in serum electrolytes balance, plasma osmolality and SBP of rats has not been reported. Present study concerns the effects of differen...

The effects of serotonin (5-hydroxytryptamine; 5-HT), and the novel anxiolytics buspirone, 8-OH-DPAT (8-hydroxy-2-[N,N-dipropylamino]-tetralin) and ipsapirone (TVXQ 7821, 2-[4-[4-[2-pyrimidinyl]-1-piperazinyl] butyl]-1,2-benzisothiazol-3[2H]one-1,1-dioxide-hydrochloride) on fiber excitability were studied in three axon systems; hippocampal Schaffer collateral fibers, cerebellar parallel fibers,...

OBJECTIVES To assess effects of a semi-acute administration of buspirone in comparison to a placebo on cognitive function and negative symptoms in patients with schizophrenia and schizoaffective disorder. METHODS In a 6-week, double-blind, placebo-controlled, independent groups study 18 subjects (14 males, four females) received in random order either placebo or buspirone (15-30 mg/day). A ne...

Buspirone (Buspar; Bristol) marks a departure from established concepts of anxiolysis. Differing substantially both in its mode of action and in the clinical expression of its action from agents such as barbiturates and benzodiazepines, it would seem to operate chiefly via the 5-HT1A subtype of serotonin receptor. Such receptor selectivity is likely to be responsible for the novel action of thi...

We used in vitro neurogenesis-based human neural stem cell (hNSCs) assays and rodent in vivo behavioral assays to identify potential novel antidepressants. A combination of buspirone and melatonin displayed antidepressant activity in these assays whereas neither buspirone nor melatonin alone showed any antidepressant-like profile. After evaluating numerous combination ratios, we determined that...

BACKGROUND Withdrawal symptoms hinder smoking cessation in nicotine-dependent smokers. This prospective, double-blind, placebo-controlled clinical trial was conducted to evaluate buspirone for nicotine withdrawal symptoms. METHODS Fifty-four heavy smokers (mean 33.1 cigarettes per day for 24 years) were randomly prescribed 30 mg/d of buspirone or placebo beginning 3 weeks before abrupt smokin...